Where Its ApprovedAnd Why Not in the US Cerebrolysin is approved for treating stroke, traumatic brain injury, and/or dementia in Austria, Germany, Russia, China, South Korea, and approximately 50 other countries across Europe and Asia
It is not an FDA-approved drug, so any clinical use is investigational and provider-supervised
How do you structure a research protocol around a 100mg GHK-Cu vial
Cazzola, M., Calzetta, L., Page, C., Jardim, J., Chuchalin, A.G., Rogliani, P., Matera, M.G
For the comparative framing with peptides in the longevity-research category, see The Best Longevity Peptides for Research in Canada